A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro by Sheng Chen et al.
LETTER TO THE EDITOR Open Access
A hybrid of B and T lymphoblastic cell line
could potentially substitute dendritic cells
to efficiently expand out Her-2/neu-specific
cytotoxic T lymphocytes from advanced
breast cancer patients in vitro
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Abstract
Adoptive transfer of cytotoxic T lymphocytes (CTLs) holds promises to cure cancer. However, this treatment is hindered
by lacking a robust way to specifically expand out CTLs. Here, we developed a hybrid of B lymphoblastic cell line and T
lymphoblastic cell line (T2 cells) as a substitute of dendritic cells, together with irradiated autologous peripheral blood
mononuclear cell (PBMC) as feeder cells and rhIL-2, to activate and expand Her-2/neu-specific CD8+ T cells from
human epidermal growth factor receptor 2 (Her-2/neu) and human leukocyte antigen (HLA)-A2 double positive
advanced breast cancer patients in vitro. These Her-2/neu-loaded T2 cells reproducibly activated and expanded out
Her-2/neu-specific CD8+ T cells to 107 in 8 weeks. Furthermore, these Her-2/neu-specific CD8+ T cells had good
sensitivity of recognition and killing Her-2/neu-overexpressed breast cancer cell line SK.BR.3. This technique gives us
another insight on how to rapidly obtain sufficient CTLs for adoptive cancer immunotherapy.
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To the editor
The current standard way to expand specific cytotoxic T
lymphocytes (CTLs) replies obtaining sufficient dendritic
cells (DCs) from patients (Additional file 1). This method
has several defects such as invasive, time-consuming,
expansive, and unstable according to patients’ physical
conditions [1–5]. Our group found that the T2 cells,
which are a cloned hybrid between the 721.174 (variant of
the B lymphoblastic cell line LCL 721) and CEMR.3
(variant of T lymphoblastic cell line CEM-C7), potentially
conform to the demands. The cells are TAP and MHC
class II deficient, but they do express HLA-A2 and
massive co-stimulatory molecules (Additional file 2:
Figure S1). These characters make T2 cells potentially
useful to study CD8+ T cell recognition of MHC class
I antigens, meanwhile, convenient to exclude from
MHC class II antigen intervention. Subsequently,
HER-2/neu(369–377) and HER-2/neu(435–443) which
scores more than 20 by SYFPEITHI prediction was
selected to load to T2 cells to expand Her-2/neu-specific
CD8+ T cells. HIV gag(77–85), insulin B chain(34–42), and
HER-2/neu(39–47) which scores minus 3 were performed
as a control (see Additional file 1: Table S1). All peptides
except low-affinity peptide HER-2/neu(39–47) could
stabilize HLA-A2 molecules on the cell membrane obvi-
ously (Additional file 3: Figure S2A).
After co-culture with CD8+ T cells from Her-2/neu
and HLA-A2 double positive advanced breast cancer pa-
tients, HER-2/neu(369–377)- and HER-2/neu(435–443)-
loaded T2 cells lead to a large secretion of IFN-γ, but
not the three controls (Additional file 3: Figure S2B).
For the expansion, starting from 1 × 105 total CD8+ T
cells that were less than 0.05% Her-2/neu-specific, nearly
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107 HER-2/neu(369–377) or HER-2/neu(435–443)-specific
CD8+ T cells were expanded out in 8 weeks with the
purity of around 85% (Fig. 1a, b). The expanded specific
CD8+ T cells got massive co-stimulatory molecules and
activation makers (Fig. 1c). The three controls got
negative results. That was expected due to extremely
low frequency of naturally occurring HIV gag(77–85) and
insulin B chain(34–42)-specific naive CD8
+ T cells as
Fig. 1 Her-2/neu-specific CD8+ T cells are efficiently expanded out by Her-2/neu-loaded T2 cells from advanced breast cancer patients. a In vitro
Her-2/neu-specific CD8+ T cells were expanded out by Her-2/neu-loaded T2 cells in addition with rhIL-2 and irradiated autologous PBMC (peptides,
HER-2/neu(39–47), HER-2/neu(369–377), and HER-2/neu(435–443), respectively). Left, proliferation assessed as uptake of [
3H] thymidine; right, total cell number
counting of specific CD8+ T cells after expansion. Nearly 1.0E + 07 Her-2/neu-specific CTLs were expanded out in 8 weeks. b Her-2/neu-specific CD8+ T
cells were verified by Her-2/neu-conjugated HLA-A*0201 Dextramer staining by fluoresence. Her-2/neu(369–377)- and Her-2/neu(435–443)-loaded T2 cells
expanded out specific CD8+ T cells with the purity of around 85%. c The expanded Her-2/neu specific CD8+ T cells expressed massive activation
makers CD25, CD40, and CD40L. The results are all from one representative of three independent experiments
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indicated in Additional file 3: Figure S2B and low
affinity HER-2/neu(39–47) peptides as showed in Additional
file 1: Table S1. We found these expanded HER-2/neu-
specific CD8+ T cells were mainly effector and effector
memory cells (Additional file 4: Figure S3).
The expanded Her-2/neu-specific CTL populations
mediated dose-dependent lysis to HLA-A2-positive and
Her-2/neu-overexpressed breast cancer cell line SK.BR.3,
but not to the three control targets (Fig. 2a). The lysis
attributed to over 50% perforin producing CTLs and more
than 80% granzyme B producing CTLs (Fig. 2b). The
cytotoxic activity against SK.BR.3 could significantly be
eliminated by W6/32, but not by IgG2 (shown in Fig. 2c).
A major finding of this study was that the Her-2/neu-
loaded T2 cells could expand out nearly 107 Her-2/neu-
specific CTLs in 8 weeks. The expanding efficiency is
equivalent to DCs previously reported by Marzocchetti
et al. [6–8]. And because the expansion was started from
Fig. 2 The expanded Her2/neu-specific CTLs well recognize and kill the related targets. a The expanded effector cells (HER-2/neu(369–377)-or HER-2/
neu(435–443)-specific CD8
+ T cells) could only lyse HLA-A2-positive and Her-2/neu-overexpressed breast cancer cell line SK.BR.3, but not the controls.
b Perforin or granzyme B secretion by expanded Her2/neu-specific effector cells was detected after co-culture with SK.BR.3. c Anti-HLA class I antibody
blocking inhibited the cytotoxic activity of the expanded Her-2/neu-specific CD8+ T cells against SK.BR.3. Mouse IgG2 antibody was added as a control.
*P < 0.05, **P < 0.01, ***P < 0.001 (ANOVA)
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CD8+ T cells which were only from 5 ml blood, with an
initial frequency of Her-2/neu-specific CD8+ T cells at
0.05%, it would be possible to amplify the expanding
quantity if we isolate the Her-2/neu-specific CD8+ T
cells firstly from more blood, 50 ml or more for
example.
We found the expanded HER-2/neu-specific CTLs
could recognize endogenous antigen on allogeneic breast
cancer cell line SK.BR.3. This is critically important be-
cause previously, many expanding techniques lead to
CTLs that could only kill targets pulsed with related
peptides but not targets that endogenously processed
the antigen of interest [9]. Yee et al. [10, 11] found low
affinity of induced CTLs leads to failure of recognition
of endogenous antigen.
Thus, T2 cells have shown promise as a convenient
tool to rapidly expand out Her-2/neu-specific CTLs in
vitro. But so far, we are not able to transfer the expanded
Her-2/neu-specific CTLs to breast cancer patients dir-
ectly as they are mixed with T2 cells, and for the same
reason, we cannot compare its anti-tumor effect with
trastuzumab in breast cancer patients either. This tech-
nique might accelerate to study expanding CTLs in vitro
and promote the development of safe and effective adop-
tive cancer immunotherapy in the future.
Additional files
Additional file 1: Materials and methods. (DOC 199 kb)
Additional file 2: Figure S1. T2 cells express more HLA-A2 and equivalent
co-stimulatory molecules compared with DC cells. (TIF 173 kb)
Additional file 3: Figure S2. Her-2/neu-loaded T2 cells can activate
related CD8+ T cells equally as DCs. a T2 cells stabilized the MHC I
molecules on the cell membrane after loading relative restricted
peptides. The mean fluorescence intensity of HLA-A2 was detected by
FACS staining before or after peptide loading. b Her-2/neu-loaded T2
cells could activate CD8+ T cells as effectively as DC cells. IFN-γ secretion
of CD8+ T cells after activation was detected by ELISA. *P < 0.05, **P <
0.01 (Student’s t test). (TIF 14741 kb)
Additional file 4: Figure S3. The expanded Her-2/neu-specific CD8+ T
cells are mainly effector and effector memory cells. CCR7 and CD45RA
expression on expanded CD8+ T cells was detected by FACS. The expanded
Her-2/neu specific CTLs were partially CCR7−CD45RA+ (effector), partially
CCR7−CD45RA− (effector memory), and rarely (about 1.62%) CCR7+CD45RA+
(naive). This representative data are from the expanded Her-2/neu(369–377)-
specific CD8+ T cells. (TIF 11635 kb)
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